BRPI0412255A - tratamento da disfunção sexual masculina - Google Patents
tratamento da disfunção sexual masculinaInfo
- Publication number
- BRPI0412255A BRPI0412255A BRPI0412255-0A BRPI0412255A BRPI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- sexual dysfunction
- male sexual
- ejaculation
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
"TRATAMENTO DA DISFUNçãO SEXUAL MASCULINA". A presente invenção refere-se -se à utilização de antagonistas de receptores de vasopressina V1a para o tratamento da disfunção sexual masculina, em particular distúrbios de ejaculação, tal como ejaculação precoce ou ejaculação rápida. A presente invenção também refere-se a um método de tratamento da disfunção sexual masculina, em particular distúrbios de ejaculação, tal como ejaculação precoce ou ejaculação rápida. A presente invenção também refere-se a ensaios para pesquisar os compostos úteis no tratamento da disfunção sexual masculina, em particular distúrbios de ejaculação, tal como ejaculação precoce ou ejaculação rápida, por pesquisa de compostos que são antagonistas de receptores de V1a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317227.7A GB0317227D0 (en) | 2003-07-23 | 2003-07-23 | Treatment of male sexual dysfunction |
| PCT/IB2004/002300 WO2005006899A1 (en) | 2003-07-23 | 2004-07-12 | Treatment of male sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412255A true BRPI0412255A (pt) | 2006-09-19 |
Family
ID=27772516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412255-0A BRPI0412255A (pt) | 2003-07-23 | 2004-07-12 | tratamento da disfunção sexual masculina |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1656183B1 (pt) |
| JP (1) | JP2006528171A (pt) |
| AT (1) | ATE380048T1 (pt) |
| BR (1) | BRPI0412255A (pt) |
| CA (1) | CA2533177A1 (pt) |
| CL (1) | CL2004001702A1 (pt) |
| GB (1) | GB0317227D0 (pt) |
| MX (1) | MXPA05014200A (pt) |
| TW (1) | TW200510424A (pt) |
| UA (1) | UA79674C2 (pt) |
| WO (1) | WO2005006899A1 (pt) |
| ZA (1) | ZA200505957B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| US7618972B2 (en) * | 2005-03-21 | 2009-11-17 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
| US20220152032A1 (en) * | 2020-11-13 | 2022-05-19 | Pharma America Holding Inc. | Sexual therapy formulation and method of treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058880A1 (fr) * | 2000-02-08 | 2001-08-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
| GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
-
2003
- 2003-07-23 GB GBGB0317227.7A patent/GB0317227D0/en not_active Ceased
-
2004
- 2004-07-06 CL CL200401702A patent/CL2004001702A1/es unknown
- 2004-07-12 WO PCT/IB2004/002300 patent/WO2005006899A1/en active IP Right Grant
- 2004-07-12 MX MXPA05014200A patent/MXPA05014200A/es unknown
- 2004-07-12 AT AT04743961T patent/ATE380048T1/de not_active IP Right Cessation
- 2004-07-12 CA CA002533177A patent/CA2533177A1/en not_active Abandoned
- 2004-07-12 EP EP04743961A patent/EP1656183B1/en not_active Expired - Lifetime
- 2004-07-12 BR BRPI0412255-0A patent/BRPI0412255A/pt not_active IP Right Cessation
- 2004-07-12 JP JP2006520920A patent/JP2006528171A/ja not_active Abandoned
- 2004-07-19 TW TW093121513A patent/TW200510424A/zh unknown
- 2004-09-02 UA UAA200508142A patent/UA79674C2/uk unknown
-
2005
- 2005-07-25 ZA ZA200505957A patent/ZA200505957B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200505957B (en) | 2006-11-29 |
| CL2004001702A1 (es) | 2005-05-13 |
| ATE380048T1 (de) | 2007-12-15 |
| WO2005006899A1 (en) | 2005-01-27 |
| CA2533177A1 (en) | 2005-01-27 |
| TW200510424A (en) | 2005-03-16 |
| EP1656183B1 (en) | 2007-12-05 |
| GB0317227D0 (en) | 2003-08-27 |
| MXPA05014200A (es) | 2006-07-03 |
| JP2006528171A (ja) | 2006-12-14 |
| UA79674C2 (en) | 2007-07-10 |
| EP1656183A1 (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200901099A1 (ru) | Соединения и способы модулирования сопряженных с g-белком рецепторов | |
| CY1117228T1 (el) | Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη | |
| AR095848A2 (es) | Derivados imidazolicos de propionamida moduladores de receptores opioides | |
| MXPA06014798A (es) | Antagonistas del receptor de hormona para liberar gonadotropina. | |
| TW200510301A (en) | Novel compounds | |
| TW200510303A (en) | Novel compounds | |
| MXPA03007513A (es) | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. | |
| SE0202241D0 (sv) | Novel Compounds | |
| TNSN07196A1 (en) | Potentiators of glutamate receptors | |
| TW200800959A (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor | |
| MX2009005461A (es) | N-oxidos de analogos de 4,5-epoxi-morfinano. | |
| TW200621244A (en) | Modulators of muscarinic receptors | |
| EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
| CL2004000545A1 (es) | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul | |
| NO20070248L (no) | Fremgangsmater for fremstilling av gonadotropinfrigjorende hormon reseptor antagonister | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| WO2007014263A3 (en) | Octahydroisoquinoline compounds as opioid receptor modulators | |
| PL1636221T3 (pl) | Związki 3-heterocyklilo-azetydynowe użyteczne jako antagoniści receptorów NK1/NK2 | |
| NO20073369L (no) | Modulatorer av muskarinreseptorer | |
| HK1077827A1 (en) | Diazabicyclononane and-decane derivatives their use as opioid receptor ligands | |
| BRPI0412255A (pt) | tratamento da disfunção sexual masculina | |
| EA200801240A1 (ru) | Новые способы получения производных циклопропиламида | |
| MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. | |
| CL2004001507A1 (es) | Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras. | |
| SE0403005D0 (sv) | New use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |